December 29, 2021

RE: Cabometyx®, Herceptin®

Cabometyx®
Effective January 17, 2022, Cabometyx® will require prior authorization (PA). Members currently using Cabometyx® will be approved for continuation of therapy. The PA criteria for reimbursement is as follows:

Cabometyx® (cabozantinib) Approval Criteria:
1. For cabozantinib monotherapy:
   a. Diagnosis of advanced renal cell carcinoma (RCC); or
   b. Diagnosis of advanced hepatocellular carcinoma (HCC); and
      i. Member has previously received sorafenib; or
   c. Diagnosis of locally advanced or metastatic differentiated thyroid cancer (DTC) in adults and pediatric members 12 years of age and older; and
      i. Disease has progressed following prior vascular endothelial growth factor (VEGF)-targeted therapy; and
      ii. Disease is radioactive iodine-refractory or member is ineligible for radioactive iodine; or

2. For cabozantinib in combination with nivolumab:
   a. Diagnosis of relapsed or surgically unresectable stage 4 disease in the initial treatment of members with advanced RCC; and
   b. Nivolumab, when used in combination with cabozantinib for RCC, will be approved for a maximum duration of 2 years.

Herceptin®
Effective January 17, 2022, Herceptin® will require PA. All trastuzumab products will require a PA to ensure appropriate use, including the preferred trastuzumab biosimilar products. The preferred trastuzumab products are Ogivri® (trastuzumab-dkst), Ontruzant® (trastuzumab-dttb), and Trazimera™ (trastuzumab-qyyyp). If a SoonerCare member is currently on therapy with Herceptin®, the medication will be approved for continuation of therapy.

The specific PA requirements for Cabometyx® and the trastuzumab products are located on the OHCA website at https://oklahoma.gov/ohca/providers/types/pharmacy/pharmacy.html in the “Oncologic” therapeutic category. A drug-specific PA form is required for Cabometyx® and for all trastuzumab products. The trastuzumab (Herceptin®, Herzuma®, Kanjinti®, Ogivri®, Ontruzant®, and Trazimera™) PA form, PHARM-133, and the Cabometyx® PA form, PHARM-197, can be found on the OHCA website at https://oklahoma.gov/ohca/providers/forms/rxforms.html.

Thank you for the services you provide to Oklahomans insured by SoonerCare!